Cite
HARVARD Citation
Tariq, B. et al. (2023). A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leukemia & lymphoma. 64 (2), pp. 329-338. [Online].